Akoya biosciences and neracare enter into an exclusive global license agreement for the development and commercialization of the immunoprint test for early-stage melanoma patient treatment decisions

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize neracare's immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize neracare's immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease
AKYA Ratings Summary
AKYA Quant Ranking